These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32514239)

  • 1. Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches.
    Alexandru O; Horescu C; Sevastre AS; Cioc CE; Baloi C; Oprita A; Dricu A
    Contemp Oncol (Pozn); 2020; 24(1):55-66. PubMed ID: 32514239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
    Qin A; Musket A; Musich PR; Schweitzer JB; Xie Q
    Neurooncol Adv; 2021; 3(1):vdab133. PubMed ID: 34806012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
    Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinases as therapeutic targets in malignant glioma.
    Ren H; Yang BF; Rainov NG
    Rev Recent Clin Trials; 2007 May; 2(2):87-101. PubMed ID: 18473993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
    Tilak M; Holborn J; New LA; Lalonde J; Jones N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Baro M; Lopez Sambrooks C; Quijano A; Saltzman WM; Contessa J
    Clin Cancer Res; 2019 Jan; 25(2):784-795. PubMed ID: 29967251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.
    Paranthaman S; Goravinahalli Shivananjegowda M; Mahadev M; Moin A; Hagalavadi Nanjappa S; Nanjaiyah N; Chidambaram SB; Gowda DV
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33321953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
    Wei Y; Erfani S; Schweer D; de Gouvea R; Qadir J; Shi J; Cheng K; Wu D; Craven R; Wu Y; Olivier T; Baldwin LA; Zhou B; Zhou Y; Zhao W; Yang BB; Ueland FR; Yang XH
    Mol Ther Oncolytics; 2023 Mar; 28():293-306. PubMed ID: 36911068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
    Schwark K; Messinger D; Cummings JR; Bradin J; Kawakibi A; Babila CM; Lyons S; Ji S; Cartaxo RT; Kong S; Cantor E; Koschmann C; Yadav VN
    Front Oncol; 2022; 12():922928. PubMed ID: 35978801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7.
    Liu Q; Li S; Qiu Y; Zhang J; Rios FJ; Zou Z; Touyz RM
    Front Cardiovasc Med; 2023; 10():1002438. PubMed ID: 36818331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification.
    Chen S; Le T; Harley BAC; Imoukhuede PI
    Front Bioeng Biotechnol; 2018; 6():92. PubMed ID: 30050899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
    Abounader R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):235-45. PubMed ID: 19192961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
    Aveic S; Tonini GP
    Cancer Cell Int; 2016; 16():62. PubMed ID: 27486382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
    Song K; Yuan Y; Lin Y; Wang YX; Zhou J; Gai QJ; Zhang L; Mao M; Yao XX; Qin Y; Lu HM; Zhang X; Cui YH; Bian XW; Zhang X; Wang Y
    Am J Cancer Res; 2018; 8(5):792-809. PubMed ID: 29888103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.
    Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI
    Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.